ACOG Committee Opinion No. 232: Tamoxifen and endometrial cancer.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006176:Gynecology / Q000592:standards*; D006801:Humans; D010818:Practice Patterns, Physicians'; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen